130 related articles for article (PubMed ID: 26183402)
21. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C transmission in young people who inject drugs: Insights using a dynamic model informed by state public health surveillance.
Gicquelais RE; Foxman B; Coyle J; Eisenberg MC
Epidemics; 2019 Jun; 27():86-95. PubMed ID: 30930214
[TBL] [Abstract][Full Text] [Related]
23. Directly observed pegylated interferon plus self-administered ribavirin for the treatment of hepatitis C virus infection in people actively using drugs: a randomized controlled trial.
Hilsden RJ; Macphail G; Grebely J; Conway B; Lee SS
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S90-6. PubMed ID: 23884072
[TBL] [Abstract][Full Text] [Related]
24. HCV epidemiology in high-risk groups and the risk of reinfection.
Midgard H; Weir A; Palmateer N; Lo Re V; Pineda JA; Macías J; Dalgard O
J Hepatol; 2016 Oct; 65(1 Suppl):S33-S45. PubMed ID: 27641987
[TBL] [Abstract][Full Text] [Related]
25. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
[TBL] [Abstract][Full Text] [Related]
26. Hepatitis C transmission and treatment as prevention - The role of the injecting network.
Hellard M; McBryde E; Sacks Davis R; Rolls DA; Higgs P; Aitken C; Thompson A; Doyle J; Pattison P; Robins G
Int J Drug Policy; 2015 Oct; 26(10):958-62. PubMed ID: 26072105
[TBL] [Abstract][Full Text] [Related]
27. Delivering direct acting antiviral therapy for hepatitis C to highly marginalised and current drug injecting populations in a targeted primary health care setting.
Read P; Lothian R; Chronister K; Gilliver R; Kearley J; Dore GJ; van Beek I
Int J Drug Policy; 2017 Sep; 47():209-215. PubMed ID: 28587943
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C reinfection after sustained virological response.
Midgard H; Bjøro B; Mæland A; Konopski Z; Kileng H; Damås JK; Paulsen J; Heggelund L; Sandvei PK; Ringstad JO; Karlsen LN; Stene-Johansen K; Pettersson JH; Dorenberg DH; Dalgard O
J Hepatol; 2016 May; 64(5):1020-1026. PubMed ID: 26780289
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis C treatment and reinfection surveillance among people who inject drugs in a low-threshold program in Oslo, Norway.
Midgard H; Ulstein K; Backe Ø; Foshaug T; Sørli H; Vennesland K; Nilssen D; Dahl EH; Finbråten AK; Wüsthoff L; Dalgard O
Int J Drug Policy; 2021 Oct; 96():103165. PubMed ID: 33642182
[TBL] [Abstract][Full Text] [Related]
30. Mortality in hepatitis C patients who achieve a sustained viral response compared to the general population.
Innes H; McDonald S; Hayes P; Dillon JF; Allen S; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley A; Bramley P; Hutchinson SJ
J Hepatol; 2017 Jan; 66(1):19-27. PubMed ID: 27545496
[TBL] [Abstract][Full Text] [Related]
31. Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes.
Innes HA; McDonald SA; Dillon JF; Allen S; Hayes PC; Goldberg D; Mills PR; Barclay ST; Wilks D; Valerio H; Fox R; Bhattacharyya D; Kennedy N; Morris J; Fraser A; Stanley AJ; Bramley P; Hutchinson SJ
Hepatology; 2015 Aug; 62(2):355-64. PubMed ID: 25716707
[TBL] [Abstract][Full Text] [Related]
32. Sofosbuvir and velpatasvir for hepatitis C virus infection in people with recent injection drug use (SIMPLIFY): an open-label, single-arm, phase 4, multicentre trial.
Grebely J; Dalgard O; Conway B; Cunningham EB; Bruggmann P; Hajarizadeh B; Amin J; Bruneau J; Hellard M; Litwin AH; Marks P; Quiene S; Siriragavan S; Applegate TL; Swan T; Byrne J; Lacalamita M; Dunlop A; Matthews GV; Powis J; Shaw D; Thurnheer MC; Weltman M; Kronborg I; Cooper C; Feld JJ; Fraser C; Dillon JF; Read P; Gane E; Dore GJ;
Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):153-161. PubMed ID: 29310928
[TBL] [Abstract][Full Text] [Related]
33. Examination of the risk of reinfection with hepatitis C among injecting drug users who have been tested in Glasgow.
McDonald SA; Hutchinson SJ; Cameron SO; Innes HA; McLeod A; Goldberg DJ
Int J Drug Policy; 2012 Sep; 23(5):353-7. PubMed ID: 22421553
[TBL] [Abstract][Full Text] [Related]
34. Low rate of reinfection among a cohort of people who use drugs successfully treated for hepatitis C virus infection in Vancouver, Canada.
Holeksa J; Magel T; Alimohammadi A; Thiam A; Yung R; Chu L; Truong D; Conway B
Int J Drug Policy; 2019 Oct; 72():177-180. PubMed ID: 31176594
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C virus prevalence and associated risk factors among Indigenous Australians who inject drugs.
Doyle M; Maher L; Graham S; Wand H; Iversen J
Aust N Z J Public Health; 2018 Feb; 42(1):52-56. PubMed ID: 29168317
[TBL] [Abstract][Full Text] [Related]
36. Belgian experience with direct acting antivirals in people who inject drugs.
Bielen R; Moreno C; Van Vlierberghe H; Bourgeois S; Mulkay JP; Vanwolleghem T; Verlinden W; Brixko C; Decaestecker J; De Galocsy C; Janssens F; Cool M; Van Overbeke L; Van Steenkiste C; D'heygere F; Cools W; Nevens F; Robaeys G
Drug Alcohol Depend; 2017 Aug; 177():214-220. PubMed ID: 28618285
[TBL] [Abstract][Full Text] [Related]
37. A Phylogenetic Analysis of Hepatitis C Virus Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy.
Akiyama MJ; Lipsey D; Ganova-Raeva L; Punkova LT; Agyemang L; Sue A; Ramachandran S; Khudyakov Y; Litwin AH
J Infect Dis; 2020 Jul; 222(3):488-498. PubMed ID: 32150621
[TBL] [Abstract][Full Text] [Related]
38. Treatment for hepatitis C virus infection among people who inject drugs attending opioid substitution treatment and community health clinics: the ETHOS Study.
Grebely J; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Phung N; Weltman MD; Day CA; Treloar C; Bath N; Haber PS; Dore GJ;
Addiction; 2016 Feb; 111(2):311-9. PubMed ID: 26451534
[TBL] [Abstract][Full Text] [Related]
39. Psychoeducation improves hepatitis C virus treatment during opioid substitution therapy: a controlled, prospective multicenter trial.
Reimer J; Schmidt CS; Schulte B; Gansefort D; Gölz J; Gerken G; Scherbaum N; Verthein U; Backmund M
Clin Infect Dis; 2013 Aug; 57 Suppl 2():S97-104. PubMed ID: 23884073
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of hepatitis C and pre-testing awareness of hepatitis C status in 1500 consecutive PWID participants at the Stockholm needle exchange program.
Kåberg M; Hammarberg A; Lidman C; Weiland O
Infect Dis (Lond); 2017 Oct; 49(10):728-736. PubMed ID: 28574295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
